Cancer gene editing drugs are launched in Denmark a bit too quickly.

The Danish health department and the drug supervision department only had a dispute for a week before passing the listing application.

This not only made Haisha feel unbelievable, but Chen Changan, who was connected to the message, was also very surprised.

"Why is it so smooth?"

"Because the aging and the continued decline in population growth rates, the Danish government must pay attention to the labor force of cancer patients."

"And our cancer gene editing drugs can enable more cancer patients to prolong their survival and return to normal work."

Guan Kou held a data table and reported to Chen Changan: "Mr. Chen, the total population of Denmark is about 5.73 million, with an average life expectancy of 80 years. The population growth rate in the past ten years has remained at around 0.4%, and the population growth rate will naturally increase by about 20,000 in a year."

"It seems that this data is pretty good, but considering that Denmark itself has a serious population aging problem, the population growth rate cannot keep up with the rate of population aging."

"Precisely because the aging population is serious, Denmark's retirement age has been increasing. Now the flexible retirement age has increased to 70 years old, both men and women are the same."

"So every year the Danish government encourages Danes to have more children, but the effect is minimal. The more developed the country, the higher the happiness index, the lower the population growth rate."

"With the labor force always insufficient and the population growth rate is not satisfactory, the labor force of tens of thousands of cancer patients is still very important to the Danish government."

"If tens of thousands of cancer patients can return to work from the hospital bed, it will be able to alleviate the problem of insufficient labor in Denmark. After all, most cancer patients are sick between the ages of 40 and 50. If treated early, there will be a good cure period."

This is how small countries are. The lives of tens of thousands of people can control a country's policies. If they change to some countries with large populations, let alone tens of thousands, even millions of patients will not be able to directly control the national policies.

Of course, this does not mean that the big country ignores people's lives. On the contrary, it is because there are too many cancer patients in big countries. A small policy change will affect millions of families. Being cautious is a normal behavior.

For Denmark, although their cancer incidence is high, there are only tens of thousands of cancer patients across the country, and even if there is something wrong, it is easier to deal with.

Moreover, Ruikang Medical's clinical trials conducted in Denmark are very effective, and there are no side effects, and there is no experimental evidence to prove that sequelae will occur in the future.

At least the current safety has been guaranteed enough to try to promote this drug.

Although gene editing technology has always had certain risks in theory, the Danish government felt that the risk was less than the benefit after comprehensive consideration!

So with a wave of his hand, he passed the listing approval!

Not only did it quickly pass the marketing approval, the Danish government also immediately included this drug into the Danish medical welfare system.

It has to be said that the Danes' welfare system is really good. When paying personal income tax and medical insurance on time, it is basically free to see a doctor, and you only need to spend a registration money. The government pays the majority of the treatment costs. Of course, the tax and medical insurance paid by the people are also used, but it is also very good.

After the approval and marketing of cancer gene-edited drugs was approved in Denmark, the Danish medical department placed an order for 5,000 gene-edited drugs to Ruikang Medical.

The price of this cancer gene editing drug from Ruikang Medical is US$50,000 per unit, equivalent to about 300,000 yuan!

If you want to say it is expensive, some relatively expensive new targeted drugs are not much cheaper. Not to mention 10,000 or 20,000 yuan per box, you can only take it for one month, and the effect is not as good as this cancer gene editing drug.

But if you want to say it is cheap, it won’t be that the price of 50,000 US dollars is very expensive even for families in developed countries. Most middle-class families only make 70,000 to 80,000 US dollars a year.

However, considering that this cancer gene editing drug only needs to be injected once, it can benefit for life, even if the growth rate of cancer cells exceeds the estimate later, at most it is only one injection again. It is not necessary to cut the flesh with a blunt knife like targeted drugs. It is a one-time transaction. If you think so, it is not too expensive.

Moreover, the Danish government paid the bill for the patients directly, so the patients didn't have to pay the money themselves, so naturally they had no objection.

Even if the Danish government has an opinion, it is useless. Ruikang can produce this drug worldwide, and the pricing power is in the hands of Ruikang Medical. The Danish government can only accept it and has no right to choose.

A first order of 50,000 US dollars and 5,000 units cost the Danish government $250 million!

Of course, some of these will become various commercial taxes and income taxes paid by Ruikang Medical in Denmark, but it is only a little bit, so Datou still entered Ruikang Medical's company account.

As for profits.

The genetic drug production line that Ruikang has just started production no longer produces cardiomyocyte healing agents, because the global demand for this drug is too great, and nearly one million units are sold every month. This small production line with a monthly output of 5,000 units cannot play any role, so Chen Changan simply outsourced all of them to Tiantan Biology.

Now this production line is working overtime to produce cancer gene-editing drugs. According to Yang Hui's calculations, the production cost per production unit is about 20,000 yuan.

The main thing is the carrier used to transport the immune weapon Crispr/cas9, which is a very expensive manufacturing cost. The Crispr/cas9 genome requires large-scale cultivation, which is quite expensive.

Just these two points account for about 90% of the production cost!

In addition to labor costs, transportation costs and taxes, it costs about 50,000 yuan for a cancer gene-edited drug from production to transportation to a hospital in Denmark.

Chen Changan's price is only 50,000 yuan, but it's just that it's very conscientious to change the unit from RMB to US dollars.

This is already considered a good person in the pharmaceutical industry!

He has already considered it. Even if it is launched in China in the future, the price will be the same as the price in Denmark, and it will also be sold for US$50,000.

If a medical company wants to open up the market globally, the first thing it needs to do is to treat everyone equally. It cannot be sold in one place at a very cheap place, but it is very expensive in one place.

The selling price of cardiomyocyte therapy agents is basically the same worldwide, with the difference in price in different places only a few hundred dollars, mainly due to the difference in tax and transportation costs of different countries.

Because artificial hematopoietic equipment is sold directly to governments of various countries, and does not involve ordinary patients in the transaction, and it is also medical equipment, Chen Changan deliberately sold it to foreign governments at a high price, which is considered to be an exporter to the domestic medical industry.

However, this treatment drug that directly involves every patient. If patients in different regions are treated differently, then sales may not be affected in order to save lives, but the corporate image and reputation will be completely destroyed.

If Ruikang sells it cheaply in China alone, as long as the price difference is greater than the two air tickets, it is very likely that patients around the world will go to China and find a hospital for treatment. They will definitely do this!

By that time, domestic medical resources will be flocked to patients around the world, which will cause domestic patients to find difficulties in seeking medical treatment.

That will have a fierce impact on the entire Chinese medical system. Chen Changan will definitely be scolded to death, or even blacklisted by the government!
Chapter completed!